Medtronic Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) decreased by 0.3% to $1.55B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 0.4%, from $1.56B to $1.55B. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher levels indicate strong short-term liquidity, while lower levels might suggest a reliance on other funding sources or a strategy to reinvest in longer-term assets.
This metric measures the amortized cost of available-for-sale debt securities that are scheduled to mature within one ye...
Standard metric for all financial institutions to demonstrate short-term solvency and cash flow management.
afs_debt_securities_amortized_cost_1y| Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|
| Value | $1.46B | $1.49B | $1.56B | $1.43B | $1.56B | $1.55B |
| QoQ Change | — | +1.8% | +4.8% | -8.2% | +8.9% | -0.3% |
| YoY Change | — | — | — | -2.1% | +4.8% | -0.4% |